ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.
Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.
Emcure Pharmaceuticals has filed its Annual Report for the financial year 2025-26 and the notice for its 45th Annual General Meeting.
Emcure Pharmaceuticals has allotted 19,100 equity shares to employees following the exercise of vested ESOPs. The paid-up capital of the company has increased accordingly.